Decitabine in combination with idarubicin within a modified busulfan/cyclophosphamide conditioning regimen for patients with advanced myelodysplastic syndrome: A prospective multicenter clinical cohort study

1Department of Hematopoietic Stem Cell Transplantation Center, State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology, Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300000, China

2Department of Hematology, Second Hospital of Hebei Medical University, Hebei Key Laboratory of Hematology, Shijiazhuang, Hebei 050000, China

3Center for Information and Resource, State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology, Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300000, China

4Department of Hematology, Qilu Hospital of Shandong University, Jinan, Shandong 250000, China

5Department of Hematology, Shanxi Bethune Hospital, Third Hospital of Shanxi Medical University, Taiyuan, Shanxi 030032, China

6Department of Hematology, Qingdao Central Hospital, University of Health and Rehabilitation Sciences, Qingdao, Shandong 266042, China

7Department of Hematology, Shandong Provincial Hospital, Cheeloo College of Medicine, Shandong University, Jinan, Shandong 250000, China

8Department of Hematology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong 250000, China

9Department of Hematology, Shengjing Hospital of China Medical University, Shenyang, Liaoning 110000, China

10Department of Hematology, Shenzhen Second People’s Hospital, The First Affiliated Hospital of Shenzhen University, Shenzhen University School of Medicine, Shenzhen, Guangdong 518000, China

11Department of Hematology, Henan Cancer Hospital, Cancer Hospital Affiliated Zhengzhou University, Zhengzhou, Henan 450000, China

12Department of Hematology, Department of Hematology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan 450000, China

Yigeng Cao, Mingyang Wang, and Fuxu Wang contributed equally to this work.

Correspondence to: Professor Ling Wang, Qingdao Central Hospital, University of Health and Rehabilitation Sciences, 127 Siliu South Road, Qingdao, Shandong 266042, China E-Mail: [email protected];

Professor Liangming Ma, Shanxi Bethune Hospital, Third Hospital of Shanxi Medical University, 99# Longcity Da Street, Taiyuan, Shanxi 030032, China E-Mail: [email protected];

Professor Chuan-fang Liu, Qilu Hospital of Shandong University, No. 107, Wenhua West Road, Jinan, Shandong 250000, China E-Mail: [email protected];

Professor Xuejun Zhang, Department of Hematology, Second Hospital of Hebei Medical University, Hebei Key Laboratory of Hematology, 215 Heping West Road, Shijiazhuang, Hebei 050000, China E-Mail: [email protected];

Professor Er-lie Jiang, Center of Haemopoietic Stem Cell Transplantation, State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology, Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300000, China E-Mail: [email protected]

How to cite this article: Cao YG, Wang MY, Wang FX, Guo WW, Ma YS, Li XY, He Y, Pang AM, Zhang RL, Zhai WH, Chen X, Ma QL, Wei JL, Yang DL, Huang Y, Feng D, Liu J, Gao X, Wen SP, Wang W, Wang T, Li Y, Fang XS, Li YC, Zhang XH, Cai Y, Wang YQ, Cao WJ, Lu RQ, Feng SZ, Guo R, Fu YW, Du X, Liu ZG, Wang X, Wang L, Ma LM, Liu CF, Zhang XJ, Han MZ, Jiang EL. Decitabine in combination with idarubicin within a modified busulfan/cyclophosphamide conditioning regimen for patients with advanced myelodysplastic syndrome: A prospective multicenter clinical cohort study. Chin Med J 2024;137:1115–1117. doi: 10.1097/CM9.0000000000002963

This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. http://creativecommons.org/licenses/by-nc-nd/4.0

留言 (0)

沒有登入
gif